Founded in 2019, Encoded Therapeutics operates in gene therapy. No public ticker exists for the company.
Encoded Therapeutics has no published valuation.
GVLEADAanother healthcare fundLEAD
GVLEAD
VenrockLEADAARCH Venture PartnersLEADMMatrix Capital ManagementLEAD
Menlo VenturesLEADRRTW InvestmentsBBoxer CapitalAAlexandria Venture Investments
ARCH VenturesMMatrix CapitalIIllumina VenturesAAltitude Life Science VenturesGVanother healthcare fundGVVenrockEncoded Therapeutics develops one-time gene therapies for severe neurological disorders, using a targeting and regulation platform designed to reach specific cell types with precision. Founded in 2019 and based in South San Francisco, its lead program, ETX101, treats Dravet syndrome, a severe form of childhood epilepsy caused by SCN1A gene variants.
In its POLARIS trials, ETX101 produced a median seizure reduction of 78% through seven months of observation at the third dose level, with no treatment-related serious adverse events reported across four dose levels. The company has since raised $275 million in a Series F round to advance ETX101 through pivotal development.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Encoded Therapeutics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Encoded Therapeutics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Encoded Therapeutics included.
The closest gene therapy peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Encoded Therapeutics is a private company; its shares do not trade on a public exchange.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
